CD3 Positive Gastric Plasmablastic Lymphoma in a HIV Negative Patient: A Case Report

Betul Bolat Kucukzeybek* Aylin Orgen Calli* Mehmet Ali Uyaroglu* Fusun Ozdemirkiran**
Aysegul Akder Sarı* Ayse Vatansever* Bahriye Payzin**

INTRODUCTION

Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell lymphoproliferative disorder [1,2,3]. It is characterized by the diffuse proliferation of large neoplastic cells resembling immunoblasts with an immunophenotype of plasma cells [1,4,5]. The incidence is high in HIV-positive patients, mostly in males. It is originally described and mostly observed in the oral cavity but may be seen in other localizations, predominantly at extranodal sites [1]. HIV positivity is less frequent in non-oral type PBL and can be seen in maxillary sinus, nasopharynx, and more rarely in the gastrointestinal tract and soft tissue [6,7].

A 47-year-old male patient diagnosed with gastric plasmablastic lymphoma with an aberrant CD3 expression will be presented below.

CASE

A 47-year-old male was referred to our hospital with gastrointestinal bleeding and an ulcero-vegetating, polypoid mass measuring 10 cm in diameter in the antrum. No pyloric involvement was detected during the upper gastrointestinal endoscopy. An endoscopic biopsy was performed subsequently. A histopathological examination of the biopsy material revealed ulcer, alterations associated with ulcer, and further presented a diffuse infiltration of atypical cells with abundant cytoplasm and pleomorphic nuclei, some with crush artifacts in lamina propria. Immunohistochemically, the tumor cells were negative for cytokeratin, CD2, CD20, and PAX5; but they were positive for CD3, MUM1, CD38, and CD138. Ki67 proliferation index was as high as 95%. The case was signed out as CD3-positive plasmablastic lymphoma with clinical, histopathological, and immunohistochemical findings. The plasmablastic lymphoma case with an aberrant CD3 expression will be presented here, which is rarely observed in stomach.

Key words: Plasmablastic lymphoma, CD3, gastric lymphoma
propria (Figure 1a, 1b, 1c). Immunohistochemically, the tumor cells were negative for cytokeratin, CD2, CD20 (figure 1d), and PAX5; but they were positive for CD3 (figure 2a), MUM1 (figure 2b), CD38, and CD138 (figure 2c). Ki67 proliferation index was 95% (figure 2d). The case was signed out as CD3 positive plasmablastic lymphoma with clinical, histopathological, and immunohistochemical findings. Bone marrow biopsy proved to be negative for infiltration. The patient received 6 cycles of R-CHOP chemotherapy regimen. The PET-CT scan was negative after chemotherapy. During the 33-month follow-up, the patient presented no recurrence.

**DISCUSSION**

Plasmablastic lymphoma is a rare and aggressive B-cell lymphoma firstly described in 1997 by Delecluse et al. in the oral cavity of the immunocompromised patients [8]. In recent years, cases have been reported in HIV-negative patients, observed in the nasopharynx, maxillary sinus, orbita, skin, lung, gastrointestinal tract, soft tissue, anus, vulva, and mediastinum [1-6, 9-11]. HIV positivity is seen in 90% of the oral PBL cases, whereas the HIV positivity in non-oral PBL cases is less prevalent. EBV-positivity percentage is almost 100% in HIV-positive oral mucosal type PBL [6]. PBL is often associated with immunodeficiency such as HIV infection and EBV plays an important role in the tumorigenesis of the HIV-associated PBL [12]. However, detection of EBV positivity in 17% of HIV-negative PBL cases suggests that EBV may not be a unique causal agent in the pathogenesis of PBL [13]. The case presented herein was not immunocompromised or HIV-positive.

Histopathologically, PBL is characterized by apoptotic cells and the proliferation of large neoplastic cells having numerous mitoses with a diffuse growth pattern. Immunohistochemically, pan B markers (CD20, CD22, PAX5, CD79a) are often negative and plasma cell associated markers (IRF4/MUM1, CD38, CD138) are strongly positive. Ki67 proliferation index is quite high and the aberrant expression of T-cell markers (CD3, CD4, CD43, CD7) is reported in rare cases [1,6,9]. Our case had a strong positivity of plasma-cell-associated markers and also of a T-cell marker, CD3. Immunohistochemically, CD3 positivity with CD20 and CD79a negativity may suggest a T-cell non-Hodgkin lymphoma in a differential diagnosis but that was excluded by the negativity of other T-cell markers (CD2, CD7) and a strong positivity of plasma-cell-associated markers.

Extramedullary plasmacytoma and plasmablastic plasma cell myeloma are other matters which should be considered for differential diagnosis as they have similar morphological and immunophenotypical features [2,6,9,14]. Clinicopathological correlation is essential in the differential diagnosis. Serum monoclonal protein negativity and high Ki67 proliferation index are also useful in this context. Serum and urine electrophoresis tests, high Ki67 proliferation index and computed tomography findings with no abnormalities of bone structures were helpful for the differential diagnosis of the case presented.

Plasmablastic lymphoma is very aggressive and most of the patients are lost within the first year of diagnosis [1]. Antiretroviral therapy and chemotherapy are reported to be quite helpful in improving the prognosis [15]. Our patient received 6 cycles of R-CHOP chemotherapy regimen. The PET-CT scan was negative
after chemotherapy. During the 33-month follow-up, the patient presented no recurrence.

Extranodal PBL is a rare and aggressive lymphoma that should be taken into account for differential diagnosis especially if the gastrointestinal tract shows a negativity with lymphoid and B-cell markers confused with poorly differentiated carcinomas; nevertheless, it poses diagnostic difficulties with T-cell lymphomas presenting aberrant expressions of T-cell markers.

REFERENCES